Return to homepagePandemic Pact

Harnessing the beneficial off-target effects of BCG vaccination to boost protection against SARS-CoV-2

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:1 publications

Grant number: 2012769

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $804,156.18

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    Dr. Nicole Messina

  • Research Location

    Australia

  • Lead Research Institution

    Murdoch Childrens Research Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Disease models

  • Special Interest Tags

    Innovation

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Health Personnel, Unspecified

Abstract

Bacillus Calmette-Guérin(BCG), the vaccine that protects against tuberculosis, also protects against other diseases. This is thought to be because BCG can boost immunity. We will investigate how BCG boosts immune responses to SARS-CoV-2 and if this improves protection against COVID-19 and the effectiveness of COVID-19 vaccines. We will combine use of mouse models with use of samples from BRACE, our 6800 participant trial testing if BCG vaccination protects against COVID-19 in healthcare workers.

1 Publication linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Effect of Bacille Calmette-Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination.